vascular endothelial growth factor a

Summary

Summary: The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.

Top Publications

  1. ncbi Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    Harold F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 20:4368-80. 2002
  2. ncbi Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
    Irene Noguera-Troise
    Regeneron Research Laboratories, 777 Old Saw Mill River Road, Tarrytown, New York 10591, USA
    Nature 444:1032-7. 2006
  3. ncbi Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Alan Sandler
    Vanderbilt University, Nashville, TN, USA
    N Engl J Med 355:2542-50. 2006
  4. ncbi Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor
    Shideng Bao
    Department of Surgery, Preston Robert Tisch Brain Tumor Center, Molecular Cancer Biology Program, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 66:7843-8. 2006
  5. ncbi VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells
    Myriam Grunewald
    Department of Molecular Biology, Hebrew University Hadassah Medical School, Jerusalem 91120, Israel
    Cell 124:175-89. 2006
  6. pmc Tumor angiogenesis
    Robert S Kerbel
    Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, and the Department of Medical Biophysics, University of Toronto, Toronto
    N Engl J Med 358:2039-49. 2008
  7. pmc Molecular mechanisms and clinical applications of angiogenesis
    Peter Carmeliet
    Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Leuven B 3000, Belgium
    Nature 473:298-307. 2011
  8. ncbi Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Nature 380:435-9. 1996
  9. pmc Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
    J A Forsythe
    Department of Physiology, University of Maryland School of Medicine, Baltimore, 21201, USA
    Mol Cell Biol 16:4604-13. 1996
  10. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003

Research Grants

  1. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2013
  2. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2012
  3. Brain mast cells and Chronic Fatigue Syndrome
    Theoharis C Theoharides; Fiscal Year: 2013
  4. Angiotensin Adrenergic Interactions in the Kidney
    Roland C Blantz; Fiscal Year: 2013
  5. Emilio B Gonzalez; Fiscal Year: 2014
  6. ENEIQUE A MESRI; Fiscal Year: 2016
  7. Priyabrata Mukherjee; Fiscal Year: 2016
  8. Targeted siRNA nanotechnology for intravesical treatment of urologicaldiseases
    Robert M Weiss; Fiscal Year: 2010
  9. Junxuan Lu; Fiscal Year: 2014
  10. JAMES FRANCIS MCGINNIS; Fiscal Year: 2015

Detail Information

Publications423 found, 100 shown here

  1. ncbi Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    Harold F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 20:4368-80. 2002
    b>Vascular endothelial growth factor A (VEGF-A), the founding member of the vascular permeability factor (VPF)/VEGF family of proteins, is an important angiogenic cytokine with critical roles in tumor angiogenesis...
  2. ncbi Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
    Irene Noguera-Troise
    Regeneron Research Laboratories, 777 Old Saw Mill River Road, Tarrytown, New York 10591, USA
    Nature 444:1032-7. 2006
    ....
  3. ncbi Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Alan Sandler
    Vanderbilt University, Nashville, TN, USA
    N Engl J Med 355:2542-50. 2006
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers...
  4. ncbi Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor
    Shideng Bao
    Department of Surgery, Preston Robert Tisch Brain Tumor Center, Molecular Cancer Biology Program, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 66:7843-8. 2006
    ..Together these data indicate that stem cell-like tumor cells can be a crucial source of key angiogenic factors in cancers and that targeting proangiogenic factors from stem cell-like tumor populations may be critical for patient therapy...
  5. ncbi VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells
    Myriam Grunewald
    Department of Molecular Biology, Hebrew University Hadassah Medical School, Jerusalem 91120, Israel
    Cell 124:175-89. 2006
    ..Together, the data suggest a model for VEGF-programmed adult neovascularization highlighting the essential paracrine role of recruited myeloid cells and a role for SDF1 in their perivascular retention...
  6. pmc Tumor angiogenesis
    Robert S Kerbel
    Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, and the Department of Medical Biophysics, University of Toronto, Toronto
    N Engl J Med 358:2039-49. 2008
  7. pmc Molecular mechanisms and clinical applications of angiogenesis
    Peter Carmeliet
    Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Leuven B 3000, Belgium
    Nature 473:298-307. 2011
    ..Recent preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies...
  8. ncbi Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Nature 380:435-9. 1996
    ....
  9. pmc Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
    J A Forsythe
    Department of Physiology, University of Maryland School of Medicine, Baltimore, 21201, USA
    Mol Cell Biol 16:4604-13. 1996
    ..VEGF mRNA was not induced by hypoxia in mutant cells that do not express the HIF-1beta (ARNT) subunit. These findings implicate HIF-1 in the activation of VEGF transcription in hypoxic cells...
  10. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
    ..VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration...
  11. ncbi Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
    Oriol Casanovas
    Department of Biochemistry and Biophysics, Comprehensive Cancer Center, and Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Cell 8:299-309. 2005
    ..These other proangiogenic signals are functionally implicated in the revascularization and regrowth of tumors in the evasion phase, as FGF blockade impairs progression in the face of VEGF inhibition...
  12. pmc HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion
    Rose Du
    Department of Neurological Surgery, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Cancer Cell 13:206-20. 2008
    ..VEGF also directly regulates tumor cell invasiveness. When VEGF activity is impaired, tumor cells invade deep into the brain in the perivascular compartment...
  13. ncbi Angiogenesis in cancer and other diseases
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 407:249-57. 2000
    ..This integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases. But owing to several unanswered questions, caution is needed...
  14. pmc miR-126 regulates angiogenic signaling and vascular integrity
    Jason E Fish
    Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA
    Dev Cell 15:272-84. 2008
    ..These findings illustrate that a single miRNA can regulate vascular integrity and angiogenesis, providing a new target for modulating vascular formation and function...
  15. ncbi Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells
    Jalees Rehman
    Krannert Institute of Cardiology, Indiana Center for Vascular Biology and Medicine, Indianapolis, Ind 46202, USA
    Circulation 109:1292-8. 2004
    ..The beneficial effects of delivered cells appear to be related to their pluripotency and ability to secrete growth factors. We examined nonadipocyte stromal cells from human subcutaneous fat as a novel source of therapeutic cells...
  16. ncbi Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms
    T Kinnaird
    Cardiovascular Research Institute, Washington, DC 20010, USA
    Circulation 109:1543-9. 2004
    ..Bone marrow cell therapy is reported to contribute to collateral formation through cell incorporation into new or remodeling vessels. However, the possible role of a paracrine contribution to this effect is less well characterized...
  17. ncbi Vascular endothelial growth factor (VEGF) and its receptors
    G Neufeld
    Department of Biology, Technion, Israel Institute of Technology, Technion City, Haifa 32000, Israel
    FASEB J 13:9-22. 1999
    ....
  18. doi Vascular endothelial growth factor a in intraocular vascular disease
    Joan W Miller
    Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    Ophthalmology 120:106-14. 2013
    ..vasculature seen in intraocular vascular disease are associated with increased expression of vascular endothelial growth factor A (VEGF), a potent endothelial-specific mitogen...
  19. pmc Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand
    Beate Heissig
    Division of Hematology Oncology, Cornell University Medical College, New York, NY 10021, USA
    Cell 109:625-37. 2002
    ..Release of sKitL by MMP-9 enables BM repopulating cells to translocate to a permissive vascular niche favoring differentiation and reconstitution of the stem/progenitor cell pool...
  20. ncbi Circulating angiogenic factors and the risk of preeclampsia
    Richard J Levine
    Division of Epidemiology, Statistics, and Prevention Research, National Institute of Child Health and Human Development, Department of Health and Human Services, Bethesda, MD 20892, USA
    N Engl J Med 350:672-83. 2004
    ..Limited data suggest that excess circulating soluble fms-like tyrosine kinase 1 (sFlt-1), which binds placental growth factor (PlGF) and vascular endothelial growth factor (VEGF), may have a pathogenic role...
  21. ncbi Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
    Guilian Niu
    Immunology Program, H Lee Moffitt Cancer Center and Research Institute, Department of Oncology, University of South Florida College of Medicine, Tampa, Florida, FL 33612, USA
    Oncogene 21:2000-8. 2002
    ..These studies provide evidence that the VEGF gene is regulated directly by Stat3 protein, and indicate that Stat3 represents a common molecular target for blocking angiogenesis induced by multiple signaling pathways in human cancers...
  22. pmc Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction
    Alessandro Fantin
    UCL Institute of Ophthalmology, University College London, London, United Kingdom
    Blood 116:829-40. 2010
    ..Our findings suggest that tissue macrophages are a target for antiangiogenic therapies, but that they could equally well be exploited to stimulate tissue vascularization in ischemic disease...
  23. pmc Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results
    Daniel F Martin
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Ophthalmology 119:1388-98. 2012
    ..To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years and to describe the impact of switching to as-needed treatment after 1 year of monthly treatment...
  24. pmc Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    G Bergers
    Department of Biochemistry and Biophysics, University of California, 513 Parnassus Avenue, San Francisco, California 94143, USA
    Nat Cell Biol 2:737-44. 2000
    ..Absence of MMP-2 does not impair induction of angiogenesis, but retards tumour growth, whereas lack of urokinase has no effect. Our results show that MMP-9 is a component of the angiogenic switch...
  25. pmc HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
    E Laughner
    Institute of Genetic Medicine, Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-3914, USA
    Mol Cell Biol 21:3995-4004. 2001
    ..These data provide a molecular basis for VEGF induction and tumor angiogenesis by heregulin-HER2 signaling and establish a novel mechanism for the regulation of HIF-1alpha expression...
  26. ncbi Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
    C Suri
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York 10591, USA
    Cell 87:1171-80. 1996
    ..Angiopoietin-1 seems to play a crucial role in mediating reciprocal interactions between the endothelium and surrounding matrix and mesenchyme...
  27. ncbi The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions
    Hiroyuki Takahashi
    Division of Genetics, Institute of Medical Science, University of Tokyo, 4 6 1 Shirokane dai, Minato ku, Tokyo, 108 8639, Japan
    Clin Sci (Lond) 109:227-41. 2005
    ..Recent progress in the molecular and biological understanding of the VEGF/VEGFR system provides us with novel and promising therapeutic strategies and target proteins for overcoming a variety of diseases...
  28. ncbi Endothelial cells and VEGF in vascular development
    Leigh Coultas
    The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8 Canada
    Nature 438:937-45. 2005
    ....
  29. pmc HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth
    Kelly L Covello
    Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Genes Dev 20:557-70. 2006
    ....
  30. pmc VEGF-Trap: a VEGF blocker with potent antitumor effects
    Jocelyn Holash
    Regeneron Pharmaceuticals, Incorporated, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Proc Natl Acad Sci U S A 99:11393-8. 2002
    ..VEGF-Trap-mediated blockade may be superior to that achieved by other agents, such as monoclonal antibodies targeted against the VEGF receptor...
  31. pmc Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease
    Azeb Tadesse Argaw
    Corinne Goldsmith Dickinson Center for MS, New York, NY, USA
    J Clin Invest 122:2454-68. 2012
    ..Collectively, these data identify blockade of VEGF-A signaling as a protective strategy to treat inflammatory CNS disease...
  32. pmc Role of platelet-derived growth factors in physiology and medicine
    Johanna Andrae
    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Genes Dev 22:1276-312. 2008
    ....
  33. ncbi Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven, Belgium
    Nat Med 7:575-83. 2001
    ..By upregulating PlGF and the signaling subtype of VEGFR-1, endothelial cells amplify their responsiveness to VEGF during the 'angiogenic switch' in many pathological disorders...
  34. ncbi VEGF and the quest for tumour angiogenesis factors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Rev Cancer 2:795-803. 2002
    ..How did this field begin, and how have we arrived at our present understanding of the role of VEGF in tumour progression...
  35. doi The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
    Paul Mitchell
    Centre for Vision Research Westmead Millennium Institute, University of Sydney, Sydney, Australia
    Ophthalmology 118:615-25. 2011
    ..To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME)...
  36. ncbi Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, California 94080, USA
    Nature 380:439-42. 1996
    ..Angiogenesis and blood-island formation were impaired, resulting in several developmental anomalies. Furthermore, VEGF-null embryonic stem cells exhibit a dramatically reduced ability to form tumours in nude mice...
  37. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  38. ncbi Diabetic retinopathy
    Robert N Frank
    Kresge Eye Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA
    N Engl J Med 350:48-58. 2004
  39. doi The role of adherens junctions and VE-cadherin in the control of vascular permeability
    Elisabetta Dejana
    FIRC Institute of Molecular Oncology, Via Adamello 16, 20139, Italy
    J Cell Sci 121:2115-22. 2008
    ..We discuss the possible use of inhibitors of SRC and other kinases, of agents that increase cAMP levels, and of inhibitors of lytic enzymes as pharmacological tools for decreasing endothelial permeability...
  40. pmc VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
    Yunjuan Sun
    Buck Institute for Age Research, Novato, California 94945, USA
    J Clin Invest 111:1843-51. 2003
    ..VEGF may, therefore, improve histological and functional outcome from stroke through multiple mechanisms...
  41. ncbi Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
    B Barleon
    Institute of Molecular Medicine, Tumor Biology Center Freiburg, Germany
    Blood 87:3336-43. 1996
    ..The results presented here suggest that monocyte chemotaxis in response to VEGF and most likely to PlGF152 is mediated by flt-1 and thus show a possible function for the VEGF-receptor flt-1...
  42. ncbi Pigment epithelium-derived factor: a potent inhibitor of angiogenesis
    D W Dawson
    Department of Microbiology Immunology, Department of Pathology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL 60611, USA
    Science 285:245-8. 1999
    ..These results suggest that PEDF may be of therapeutic use, especially in retinopathies where pathological neovascularization compromises vision and leads to blindness...
  43. ncbi Induction of pancreatic differentiation by signals from blood vessels
    E Lammert
    Department of Molecular and Cellular Biology, Howard Hughes Medical Institute, Harvard University, 7 Divinity Avenue, Cambridge, MA 02138, USA
    Science 294:564-7. 2001
    ..These results indicate that vessels not only provide metabolic sustenance, but also provide inductive signals for organ development...
  44. pmc Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis
    Christiana Ruhrberg
    Endothelial Cell Biology Laboratory, Cancer Research UK London Research Institute, London WC2A 3PX, United Kingdom
    Genes Dev 16:2684-98. 2002
    ..We conclude that differential VEGF-A isoform localization in the extracellular space provides a control point for regulating vascular branching pattern...
  45. doi Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
    Daniel Y C Heng
    FRCPC, Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
    J Clin Oncol 27:5794-9. 2009
    ..There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF) -targeted therapy...
  46. pmc Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
    Petra Hamerlik
    Danish Cancer Society Research Center and Centre for Genotoxic Stress Research, DK 2100 Copenhagen, Denmark
    J Exp Med 209:507-20. 2012
    ..We propose that direct inhibition of VEGFR2 kinase may block the highly dynamic VEGF-VEGFR2-NRP1 pathway and inspire a GBM treatment strategy to complement the currently prevalent ligand neutralization approach...
  47. ncbi Pathophysiological consequences of VEGF-induced vascular permeability
    Sara M Weis
    Department of Pathology and Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California 92093 0803, USA
    Nature 437:497-504. 2005
    ..Therefore, by blocking the vascular permeability promoting effects of VEGF it may be feasible to reduce tissue injury after ischaemic disease and minimize the invasive properties of circulating tumour cells...
  48. pmc Mechanisms of adverse effects of anti-VEGF therapy for cancer
    T Kamba
    Department of Urology, Kyoto University, 54 Kawahara cho, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Br J Cancer 96:1788-95. 2007
    ..These changes are generally manageable and pose less risk than the tumours being treated, but they highlight the properties shared by tumour vessels and the vasculature of normal organs...
  49. pmc Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
    Marta Pàez-Ribes
    Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, 08907 L Hospitalet de Llobregat, Spain
    Cancer Cell 15:220-31. 2009
    ....
  50. ncbi Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis
    Christophe Corpechot
    Service d Hepatologie, the INSERM Unit 402, the Laboratoire Commun de Biologie Moléculaire, the Service d Anatomie et de Cytologie Pathologiques, Centre Hospitalier Universitaire Saint Antoine, Paris, France
    Hepatology 35:1010-21. 2002
    ..In conclusion, the present study provides further evidence that hepatocellular hypoxia and angiogenesis progress together with fibrogenesis after liver injury and that hypoxia directly contributes to the progression of liver fibrosis...
  51. ncbi Regulation of tight junctions and loss of barrier function in pathophysiology
    Nicole S Harhaj
    Penn State Retina Research Group, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA
    Int J Biochem Cell Biol 36:1206-37. 2004
    ....
  52. pmc VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis
    Satoshi Hirakawa
    Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
    J Exp Med 201:1089-99. 2005
    ..This newly identified mechanism of inducing lymph node lymphangiogenesis likely contributes to tumor metastasis, and therefore, represents a new therapeutic target for advanced cancer and/or for the prevention of metastasis...
  53. ncbi Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
    Rakesh K Jain
    E L Steele Lab for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, COX 7, 100 Blossom Street, Boston, MA 02114, USA
    Science 307:58-62. 2005
    ....
  54. doi Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial
    Usha Chakravarthy
    Institute of Clinical Science, The Queen s University of Belfast, Belfast, Ireland
    Ophthalmology 119:1399-411. 2012
    ..To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD)...
  55. pmc Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis
    M Hellstrom
    Department of Medical Biochemistry, Goteborg University, SE 405 30 Goteborg, Sweden
    J Cell Biol 153:543-53. 2001
    ....
  56. doi Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha
    A Soeda
    Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Oncogene 28:3949-59. 2009
    ..This study illustrates the importance of the tumor microenvironment in determining cellular behavior...
  57. doi Anti-angiogenesis therapy in cancer: current challenges and future perspectives
    Farbod Shojaei
    Oncology Research Unit, Pfizer La Jolla, CA 92121, United States
    Cancer Lett 320:130-7. 2012
    ..Investigations in clinic and preclinical models have provided some molecular and cellular mechanisms for the above challenges. This review aims to provide a concise update from recent findings...
  58. ncbi Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
    G Thurston
    Department of Anatomy and Cardiovascular Research Institute, University of California, San Francisco, CA 94143 0452, USA
    Science 286:2511-4. 1999
    ..Ang1 therefore may be useful for reducing microvascular leakage in diseases in which the leakage results from chronic inflammation or elevated VEGF and, in combination with VEGF, for promoting growth of nonleaky vessels...
  59. ncbi Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
    Hans Peter Gerber
    Departments of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Res 65:671-80. 2005
    ..Finally, safety pharmacology studies with bevacizumab in cynomolgus monkeys showed that this agent is generally well tolerated with no unexpected adverse events...
  60. ncbi VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin
    Julie Gavard
    Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, DHHS, Bethesda, MD 20892 4340, USA
    Nat Cell Biol 8:1223-34. 2006
    ....
  61. pmc Autocrine VEGF signaling is required for vascular homeostasis
    Sunyoung Lee
    Department of Molecular, Cellular and Developmental Biology, Jonsson Comprehensive Cancer Center and Molecular Biology Institute, UCLA, Los Angeles, CA 90095, USA
    Cell 130:691-703. 2007
    ..These results reveal a cell-autonomous VEGF signaling pathway that holds significance for vascular homeostasis but is dispensable for the angiogenic cascade...
  62. doi Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
    Peter Carmeliet
    Vesalius Research Center, VIB, K U Leuven, Campus Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Nat Rev Drug Discov 10:417-27. 2011
    ..Here, we discuss the mechanisms, benefits, limitations and possible clinical translation of vessel normalization for cancer and other angiogenic disorders...
  63. ncbi Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
    John Ridgway
    Tumor Biology and Angiogenesis, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 444:1083-7. 2006
    ..Therefore, targeting Dll4 might represent a broadly efficacious and well-tolerated approach for the treatment of solid tumours...
  64. doi FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
    Christian Fischer
    Department of Hepatology and Gastroenterology, Charite Universitatsmedizin, Berlin, Germany
    Nat Rev Cancer 8:942-56. 2008
    ..Hopefully, other agents with complementary mechanisms, such as those that target placental growth factor, will offer novel opportunities for improved treatment...
  65. doi Biomarkers to predict the clinical efficacy of bevacizumab in cancer
    Adrian M Jubb
    Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Lancet Oncol 11:1172-83. 2010
    ..Many questions relating to these and other surrogate biomarkers, however, remain unanswered and their clinical usefulness has yet to be proven...
  66. ncbi Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain
    Abner Louissaint
    Department of Neurology and Neuroscience, Cornell University Medical Center, 1300 York Avenue, New York, NY 10021, USA
    Neuron 34:945-60. 2002
    ..These findings suggest a causal interaction between testosterone-induced angiogenesis and neurogenesis in the adult forebrain...
  67. doi Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Nat Rev Clin Oncol 6:507-18. 2009
    ..Nonetheless, anti-VEGF therapy has enhanced the arsenal of anticancer therapies and has provided new insights into the biology of malignancy...
  68. pmc Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia
    Sharon E Maynard
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    J Clin Invest 111:649-58. 2003
    ..These observations suggest that excess circulating sFlt1 contributes to the pathogenesis of preeclampsia...
  69. doi Developmental and pathological angiogenesis
    Alicia S Chung
    Genentech, Inc, South San Francisco, California 94080, USA
    Annu Rev Cell Dev Biol 27:563-84. 2011
    ..We also discuss current knowledge of physiological angiogenic processes as well as their disruptions in pathological processes, particularly tumorigenesis...
  70. ncbi Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors
    D A Antonetti
    Penn State Retina Research Group, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA
    J Biol Chem 274:23463-7. 1999
    ..In conclusion, VEGF rapidly increases occludin phosphorylation as well as the tyrosine phosphorylation of ZO-1. Phosphorylation of occludin and ZO-1 likely contribute to regulated endothelial paracellular permeability...
  71. pmc Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung
    Chun Geun Lee
    Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale University School of Medicine, 300 Cedar Street, 441c TAC, New Haven, Connecticut 06520 8057, USA
    Nat Med 10:1095-103. 2004
    ..Thus, VEGF is a mediator of vascular and extravascular remodeling and inflammation that enhances antigen sensitization and is crucial in adaptive T(H)2 inflammation. VEGF regulation may be therapeutic in asthma and other T(H)2 disorders...
  72. doi Diverse roles for VEGF-A in the nervous system
    Francesca Mackenzie
    UCL Institute of Ophthalmology, University College London, 11 43 Bath Street, London, UK
    Development 139:1371-80. 2012
    b>Vascular endothelial growth factor A (VEGF-A) is best known for its essential roles in blood vessel growth...
  73. pmc Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases
    Vera Eremina
    The Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Clin Invest 111:707-16. 2003
    ..Our data demonstrate that tight regulation of VEGF-A signaling is critical for establishment and maintenance of the glomerular filtration barrier and strongly supports a pivotal role for VEGF-A in renal disease...
  74. pmc VEGF inhibition and renal thrombotic microangiopathy
    Vera Eremina
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
    N Engl J Med 358:1129-36. 2008
    ..These observations provide evidence that glomerular injury in patients who are treated with bevacizumab is probably due to direct targeting of VEGF by antiangiogenic therapy...
  75. pmc Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival
    E Schipani
    Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Genes Dev 15:2865-76. 2001
    ....
  76. doi HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha
    Zoltan Arany
    Dana Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 451:1008-12. 2008
    ..PGC-1alpha may provide a novel therapeutic target for treating ischaemic diseases...
  77. pmc Expression and role of VEGF in the adult retinal pigment epithelium
    Knatokie M Ford
    Schepens Eye Research Institute Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts 02114, USA
    Invest Ophthalmol Vis Sci 52:9478-87. 2011
    ..VEGF blockade is a widely used treatment for neovascular diseases such as wet age-related macular degeneration (AMD). Therefore, it was sought in this study to evaluate the expression and role of endogenous VEGF in RPE...
  78. pmc Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
    T Murohara
    Department of Medicine Cardiology and Department of Cardiothoracic Surgery and Biomedical Research, St Elizabeth s Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02135, USA
    J Clin Invest 101:2567-78. 1998
    ....
  79. pmc Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts
    Tetsuichiro Inai
    Cardiovascular Research Institute, Comprehensive Cancer Center, and Department of Anatomy S1363, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 0452, USA
    Am J Pathol 165:35-52. 2004
    ..Early loss of endothelial fenestrations in RIP-Tag2 tumors is a clue that vessel phenotype may be predictive of exceptional sensitivity to these inhibitors...
  80. pmc Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development
    Nicholas W Gale
    Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Proc Natl Acad Sci U S A 101:15949-54. 2004
    ..In summary, Dll4 appears to be a major trigger of Notch receptor activities previously implicated in arterial and vascular development, and it may represent a new opportunity for pro- and anti-angiogenic therapies...
  81. ncbi Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of
    Young Sup Yoon
    Division of Cardiovascular Research, Caritas St Elizabeth s Medical Center, Tufts University School of Medicine, Boston, Mass 02135, USA
    Circulation 111:2073-85. 2005
    ..Diabetic cardiomyopathy (DCM) is characterized by microvascular pathology and interstitial fibrosis, which leads to progressive heart failure; however, the pathogenesis of DCM remains uncertain...
  82. pmc Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors
    Magali Saint-Geniez
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, USA
    PLoS ONE 3:e3554. 2008
    ....
  83. doi Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor
    Alessandro Galan
    S Antonio Hospital, Department of Ophthalmology, Padova, Italy
    Ophthalmology 117:1769-74. 2010
    ..Previous studies investigated the possible association between VEGF-A gene polymorphisms and AMD, with contrasting data. No study examined the possible role of VEGF receptor KDR gene polymorphisms...
  84. pmc Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia
    H J Marti
    Department of Molecular Cell Biology, the Max Planck Institute for Physiological and Clinical Research, Bad Nauheim, Germany
    Am J Pathol 156:965-76. 2000
    ..Exogenous support of this natural protective mechanism might lead to enhanced survival after stroke...
  85. pmc Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development
    Chenghua Gu
    Department of Neuroscience, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA
    Dev Cell 5:45-57. 2003
    ..Therefore, Npn-1 is a multifunctional receptor that mediates the activities of structurally distinct ligands during development of the heart, vasculature, and nervous system...
  86. ncbi Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis
    Jin Hur
    Cardiovascular Laboratory, Clinical Research Institute, Seoul National University Hospital, Korea
    Arterioscler Thromb Vasc Biol 24:288-93. 2004
    ..Endothelial progenitor cells (EPC) in one study group is not the same as EPC in other investigators, suggesting that EPC is not a single type of cell population. In this study, we tried to demonstrate the heterogeneity of EPC...
  87. ncbi Vascular endothelial growth factor: basic science and clinical progress
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Endocr Rev 25:581-611. 2004
    ..Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration...
  88. ncbi Angiogenesis in brain tumours
    Rakesh K Jain
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
    Nat Rev Neurosci 8:610-22. 2007
    ..This creates a window of opportunity for optimally combining chemotherapeutics and radiation...
  89. ncbi IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway
    Dung Fang Lee
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cell 130:440-55. 2007
    ..Our findings identify a pathway that is critical for inflammation-mediated tumor angiogenesis and may provide a target for clinical intervention in human cancer...
  90. pmc Identification of telocytes in skeletal muscle interstitium: implication for muscle regeneration
    L M Popescu
    Department of Cellular and Molecular Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
    J Cell Mol Med 15:1379-92. 2011
    ..We also described non-satellite (resident) progenitor cell niche. In culture, TCs (but not satellite cells) emerge from muscle explants and form networks suggesting a key role in muscle regeneration and repair, at least after trauma...
  91. doi AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer
    Luca Gianni
    Department of Medical Oncology, San Raffaele Hospital, Via Olgettina 60, Milan, Italy
    J Clin Oncol 31:1719-25. 2013
    ..High baseline plasma vascular endothelial growth factor A (VEGF-A) concentrations were associated with greater bevacizumab benefit (not statistically ..
  92. ncbi Vascular endothelial growth factors and angiogenesis in eye disease
    A N Witmer
    Ocular Angiogenesis Group, Department of Ophthalmology, University of Amsterdam, Amsterdam, The Netherlands
    Prog Retin Eye Res 22:1-29. 2003
    ..On the other hand, this paracrine relation and other physiological functions of VEGFs may be endangered by therapeutic VEGF inhibition, as is currently used in several clinical trials in DR and AMD...
  93. pmc Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy
    Masuko Ushio-Fukai
    Department of Pharmacology, Center for Lung and Vascular Biology, University of Illinois at Chicago, 835 S Wolcott, M C868, E403 MSB, Chicago, IL 60612, USA
    Cancer Lett 266:37-52. 2008
    ..Understanding these mechanisms may provide insight into the NADPH oxidase and redox signaling components as potential therapeutic targets for tumor angiogenesis...
  94. pmc Corneal avascularity is due to soluble VEGF receptor-1
    Balamurali K Ambati
    Department of Ophthalmology, Medical College of Georgia and Augusta Veterans Affairs Medical Center, Augusta, Georgia 30907, USA
    Nature 443:993-7. 2006
    ....
  95. pmc Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha
    R Ravi
    Johns Hopkins Oncology Center, Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 USA
    Genes Dev 14:34-44. 2000
    ..These results indicate that amplification of normal HIF-1-dependent responses to hypoxia via loss of p53 function contributes to the angiogenic switch during tumorigenesis...
  96. ncbi Osteogenesis and angiogenesis: the potential for engineering bone
    J M Kanczler
    Bone and Joint Research Group, Centre for Human Development, Stem Cells and Regeneration, Developmental Origins of Health and Disease, Institute of Developmental Sciences, University of Southampton, Southampton, SO16 6YD
    Eur Cell Mater 15:100-14. 2008
    ..Elucidation of the processes of angiogenesis, osteogenesis and tissue engineering strategies offer exciting future therapeutic opportunities for skeletal repair and regeneration in orthopaedics...
  97. pmc Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
    John M L Ebos
    Division of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, S 217 Research Building, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada
    Nat Rev Clin Oncol 8:210-21. 2011
    ..Improved preclinical assessment of all stages of metastatic disease should be a priority for future antiangiogenic drug discovery and development...
  98. doi Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs
    Astrid A M van der Veldt
    Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
    Cancer Cell 21:82-91. 2012
    ..These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs...
  99. ncbi Endochondral ossification: how cartilage is converted into bone in the developing skeleton
    E J Mackie
    School of Veterinary Science, University of Melbourne, Parkville, Victoria 3010, Australia
    Int J Biochem Cell Biol 40:46-62. 2008
    ..This review, which places an emphasis on recent advances and current areas of debate, discusses the complex interactions between cell types and signalling pathways that govern endochondral ossification...
  100. doi Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development
    Beate M Lichtenberger
    Institute for Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A 1090 Vienna, Austria
    Cell 140:268-79. 2010
    ..Moreover, Flt1 is upregulated in human SCC, and its inhibition in SCC cells impairs proliferation. Thus, in addition to regulating angiogenesis, VEGF has to be considered as a potent growth factor for epidermal tumors...
  101. pmc Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis
    H Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Gut 52:1347-54. 2003
    ..It has been shown that expression of the potent angiogenic factor, vascular endothelial growth factor (VEGF), and its receptors, flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2), increased during the development of liver fibrosis...

Research Grants80

  1. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2013
    ..Also, there will be a measurement of pressure in the eye and thickness of the cornea. To study patients'DNA, the researchers will obtain a bloo..
  2. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2012
    ..Also, there will be a measurement of pressure in the eye and thickness of the cornea. To study patients'DNA, the researchers will obtain a bloo..
  3. Brain mast cells and Chronic Fatigue Syndrome
    Theoharis C Theoharides; Fiscal Year: 2013
    ..The proposed research is hypothesis-driven, is based on strong preliminary evidence, is innovative with high likelihood for novel findings with applicability to humans. ..
  4. Angiotensin Adrenergic Interactions in the Kidney
    Roland C Blantz; Fiscal Year: 2013
    ....
  5. Emilio B Gonzalez; Fiscal Year: 2014
    ..These studies may help to devise new more specific and less harmful modalities than the anticoagulation or general immunosuppression currently used to treat and prevent thrombosis in patients with aPL Abs. ..
  6. ENEIQUE A MESRI; Fiscal Year: 2016
    ..So our work will allow us to not only to identify mechanisms of KS carcinogenesis but also will help to identify potential new target and new drugs for anti-KS therapy. ..
  7. Priyabrata Mukherjee; Fiscal Year: 2016
    ....
  8. Targeted siRNA nanotechnology for intravesical treatment of urologicaldiseases
    Robert M Weiss; Fiscal Year: 2010
    ..Our first test of these nanoparticles will use a mouse model of bladder cancer. Thus, we can determine the therapeutic potential of siRNA for treatment of urologic diseases. ..
  9. Junxuan Lu; Fiscal Year: 2014
    ..These multiple targeting activities plus published work supporting anti- angiogenesis activity provide strong rationale for testing the efficacy of PGG for prostate cancer chemoprevention. ..
  10. JAMES FRANCIS MCGINNIS; Fiscal Year: 2015
    ....
  11. Sharon M Moe; Fiscal Year: 2014
    ..Both of these problems may be linked. The purpose of this study is to determine if a commonly used group of drugs, bisphosphonates, may help both bone and heart/blood vessel disease and determine the mechanism the drugs work. ..
  12. ANDREW GREGORY SIKORA; Fiscal Year: 2015
    ..abstract_text> ..
  13. Christie P Thomas; Fiscal Year: 2014
    ....
  14. A Bifunctional Katp Channel Activator and Redox Mimetic for BPD
    Kanneganti Murthy; Fiscal Year: 2013
    ....
  15. C Michael Hart; Fiscal Year: 2016
    ..The results of this proposal can thereby define novel and effective therapeutic strategies to regulate programs of gene expression involved in PH pathogenesis. ..
  16. Phosphotyrosine signaling pathways controlling tracheal tube geometry
    KAI G ZINN; Fiscal Year: 2013
    ..We can also analyze tyrosine phosphorylation of the proteins and determine if they physically interact with each other in the embryo. ..
  17. Mechanisms of Angiogenesis in Retinopathy of Prematurity
    Mary Elizabeth Hartnett; Fiscal Year: 2009
    ..g., dihydroethidium);and NADPH oxidase activation. ..
  18. SAMUEL BRANDON STEPHENS; Fiscal Year: 2015
    ..Thus, through this award, I will gain training and generate crucial reagents necessary to launch my independent research program and obtain a tenure-track assistant professorship. ..
  19. Role of Potent Trophic Factors on Glia and Motor Neurons in ALS
    Brian K Kaspar; Fiscal Year: 2013
    ..We will subsequently test the optimal combination of these factors using gene delivery in a rodent model of this devastating disease in order to define an optimal therapy for this debilitating disorder. ..
  20. MARY ELIZABETH RUTH HARTNETT; Fiscal Year: 2016
    ..g., dihydroethidium);and NADPH oxidase activation. ..
  21. Neuropilin and semaphorin, anti-angiogenesis activities and mechanisms
    Michael Klagsbrun; Fiscal Year: 2009
    ..abstract_text> ..
  22. Anti-Fibrotic Therapy for Scleroderma/SSc
    Latha Paka; Fiscal Year: 2010
    ..The objective of this application is to evaluate a lead small- molecule drug candidate in two preclinical models of scleroderma/SSc to advance to SBIR Phase-II project with the ultimate objective of bringing our drug to clinical trials. ..
  23. Bingmei M Fu; Fiscal Year: 2014
    ....
  24. ANGIOTENSIN II SIGNAL TRANSDUCTION
    Bradford C Berk; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: The healing of tissues after surgery or trauma is critical for long-term survival. The proposed work will study novel mechanisms by which blood vessels grow in response to tissue injury. ..
  25. VEGF Regulation of Hepatic Erythropoietin Synthesis
    Calvin Kuo; Fiscal Year: 2009
    ....
  26. The lymph node microenvionment in tumor metastasis
    Judith A Varner; Fiscal Year: 2012
    ..The studies proposed in this application are likely to lead to the development and testing of new agents to diagnose and prevent or treat metastatic cancer. ..
  27. JULIE MARIE VOSE; Fiscal Year: 2016
    ..The BMT/CTN including our consortium will be the only clinical cooperative group to accomplish this goal. ..
  28. CCR3: a molecular marker for neovascular AMD
    Jayakrishna Ambati; Fiscal Year: 2010
    ....
  29. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2011
    ..Nanotechnology has made major contributions to BrCa therapy. We propose an innovative nanotechnology-based approach for BrCa prevention and treatment that could significantly impact patient care. ..
  30. Mitochondrial Oxidative Stress in the Retinal Pigment Epithelium as a Model for A
    Alfred S Lewin; Fiscal Year: 2013
    ..This project seeks to establish a mouse model of the pathology related to AMD and to use this model to test potential therapies for the atrophic form of the disease. ..
  31. Rheologic and Vascular Modulators in Sickle Vaso-occlusion
    Dhananjay K Kaul; Fiscal Year: 2012
    ..The proposed in vivo studies are expected to provide insights into the adverse and beneficial effects of HIF-1[unreadable] and NO in SCD, which may lead to new therapeutic strategies. ..
  32. DAVID ANTONETTI; Fiscal Year: 2016
    ..Further, the proposal will explore the link between vascular permeability and angiogenesis and the role of the tight junction protein occludin in endothelial cell growth control. ..
  33. FUNCTIONAL AND TARGETING POLYMERIC GENE CARRIERS
    Sung Wan Kim; Fiscal Year: 2012
    ..In this application, we propose to develop a novel bioreducible polymer to deliver VEGF gene to primary myoblasts for the treatment of acute myocardial infarct to address these short- comings of current therapeutic strategies. ..
  34. Genetic Basis for Impaired Angiogenic Signaling in BPD
    STEVEN HERBERT ABMAN; Fiscal Year: 2012
    ..abstract_text> ..
  35. Downregulation of Rod Metabolism in Retinopathy of Prematurity
    JAMES DANIEL AKULA; Fiscal Year: 2010
    ..Thus, suppression of metabolically demanding processes in the rods promises preservation of visual function and prevention of vascular disease. ..
  36. STEVEN HERBERT ABMAN; Fiscal Year: 2015
    ..In this renewal, we propose a series of integrative studies that incorporate physiologic, cell and molecular approaches towards understanding BPD. ..
  37. Gene-Engineered and Targeted Stem Cell Therapy for Myeloma
    Selvarangan Ponnazhagan; Fiscal Year: 2013
    ..Successful completion of these studies will allow us to initiate phase-1 human clinical trials. ..
  38. Mechanism and therapy for arteriovenous malformation
    Suk Paul Oh; Fiscal Year: 2013
    ..Results from this study map provide important novel insights for developing therapeutic reagents for controlling development of AVMs. ..
  39. Utpal Sen; Fiscal Year: 2015
    ..abstract_text> ..
  40. Endothelial Progenitor Cells in Brain Arteriovenous Malformations
    Yongmei Chen; Fiscal Year: 2010
    ..Identification of EPCs as an operant process in brain AVMs can suggest lines of investigation to develop new treatment modalities. ..
  41. NFAT Signaling and Down Syndrome
    Gerald R Crabtree; Fiscal Year: 2012
    ..We will test this hypothesis and if correct find molecule that correct the balance and thereby develop new treatments for some of the disabling characteristics of Down Syndrome. ..
  42. Mark E Kleinman; Fiscal Year: 2015
    ....
  43. MOHAMED AL SAYED AL-SHABRAWEY; Fiscal Year: 2016
    ....
  44. Experimental engineering of ovarian grafting to promote angiogenesis for fertilit
    GLENN LEWIS SCHATTMAN; Fiscal Year: 2010
    ..This research project will fill the knowledge gap about the biology of revascularization of ovarian grafts, which limits the fraction of surviving follicles, and will test two strategies aimed at enhancing angiogenesis. ..
  45. Role of Id1 in NSCLC Progression and Metastasis
    Srikumar P Chellappan; Fiscal Year: 2013
    ..We believe that an in-depth mechanistic analysis as proposed in this application will lead to the development of novel therapeutic agents for non-small cell lungs cancer based on targeting the Id1 protein. ..
  46. George L King; Fiscal Year: 2016
    ....
  47. Souheil El-Chemaly; Fiscal Year: 2014
    ..In addition, it will pave the way for the development of novel strategies to tret acute rejection in lung transplant recipients. ..
  48. Regulatory targets and pathogenic mechanisms of anthrax edema factor
    Jin Mo Park; Fiscal Year: 2011
    ..Our hope is that these efforts will lead to the discovery of new targets for the treatment of anthrax and other infectious diseases. ..
  49. Redox Regulation of SERCA by Nitric Oxide
    Richard A Cohen; Fiscal Year: 2013
    ..Our proposed studies intend to demonstrate the role for this mechanism in vivo using mouse models of diabetic vascular disease, including a mouse that expresses a mutant SERCA that lacks the key thiol. ..
  50. Sonia M Najjar; Fiscal Year: 2016
    ..Answering these questions will delineate new CEACAM1-dependent mechanisms underlying atherosclerosis along the liver/endothelial cell axis, and pinpoint sites of pharmacologic intervention. ..
  51. Prakash R Rai; Fiscal Year: 2014
    ..This provides the potential for rapid screening to establish individualized patient-specific molecular targets and forms the basis for designing personalized prevention and treatments. ..
  52. Reza Dana; Fiscal Year: 2016
    ....
  53. ANDV Induced Responses of Hypoxic Endothelial Cells
    Erich R Mackow; Fiscal Year: 2012
    ..These studies are likely to identify the mechanism of leakage and provide therapeutic approaches for reducing ANDV disease. ..
  54. Inner Ear Impact of Chronic Middle Ear Inflammation
    DENNIS ROYAL TRUNE; Fiscal Year: 2013
    ..Finally, various treatments will be targeted to these specific phases of inflammation to suppress the immune responses and protect the inner ear from permanent damage. ..
  55. Irwin H Gelman; Fiscal Year: 2014
    ..These studies will elucidate how the loss of SSeCKS expression in prostate cancer increases disease progression by allowing PKC to be hyperactivated and dysregulated. ..
  56. Role of Monocyte Chemoattractant Protein (MCP)-1 in Liver Regeneration
    KRISTEN ANDREA MITCHELL; Fiscal Year: 2010
    ..Finally, this project provides an opportunity for undergraduates at Boise State University to participate in biomedical research and gain an appreciation of the complex regulatory mechanisms that govern regeneration. ..
  57. Transscleral Transport & Polymeric Delivery of Antibody & Steroids for Macular Ed
    Ashim K Mitra; Fiscal Year: 2010
    ..This novel delivery system may provide added stability to steroids and bevacizumab and six-month sustained delivery from a single episcleral administration. ..
  58. Frank W Sellke; Fiscal Year: 2016
    ..The results of these studies may have significant implications regarding the recovery of diabetic and other patients after cardiac surgery involving cardioplegia and CPB. ..
  59. Preventing lethal hemorrhagic fever caused by hantaviruses by preserving endothel
    ALAN L MUELLER; Fiscal Year: 2012
    ..Specific Aim 2: Investigate dose-response efficacy of Slit2N against ANDV. Specific Aim 3: Investigate efficacy of delayed therapy with Slit2N against ANDV. Specific Aim 4: Investigate efficacy of Slit2N in combination with ribavirin. ..
  60. Characterizaton of Motility Factor Receptor
    Avraham Raz; Fiscal Year: 2012
    ..It is expected that these studies will lead to a better diagnosis, treatment and development of rational therapy. ..
  61. Blood Pressure -- Determinants &Controllers
    Allen W Cowley; Fiscal Year: 2012
    ....
  62. Neurotrophic Factors: Genetic Variation and Serum Levels in Brain Aging
    Sudha Seshadri; Fiscal Year: 2010
    ....
  63. Improve Wound Healing with HIF-CA5 DNA Vector and Electroporation
    John W Harmon; Fiscal Year: 2010
    ..Building on the promising pre- clinical data generated to date, the objective of the proposed STTR program is to bring the CA5 product candidate into clinical testing. ..
  64. Ocular Lymphangiogenesis
    DANIEL J CARR; Fiscal Year: 2010
    ....
  65. Perlecan modulates VEGF Bio-Availability in Human Osteoarthritic Cartilage
    RONALD GOMES; Fiscal Year: 2009
    ..The proposed research has relevance to public health, because articular cartilage degradation is a primary pathology associated with osteoarthritis. Thus, findings are expected to be applicable to the health of humans. ..
  66. Mechanisms of VEGF-A regulated tumor lymphangiogenesis
    Sophia Ran; Fiscal Year: 2007
    ..Because metastasis is a primary cause of mortality from cancer, these studies have the potential to significantly improve health outcomes in a large number of cancer patients. [unreadable] [unreadable] [unreadable]..
  67. Therapeutic Evaluation of Magnetic Nanoprobes Specific for Malignant Tumor Marker
    Rheal A Towner; Fiscal Year: 2010
    ..Studying a potentially effective anti- tumor therapeutic agent, as well as developing novel in vivo diagnostic and predictive procedures may significantly impact patient prognosis and survivability in the future. ..
  68. REGULATION OF VEGF EXPRESSION IN PLACENTA AND MEMBRANES
    CECILIA CHEUNG; Fiscal Year: 2004
    ..Results from these studies will promote understanding of amniotic fluid volume regulation, and provide important information for diagnosis and management of amniotic fluid disorders in human pregnancy. ..
  69. Bone Tissue Engineerig: Effect of Dynamic Perfusion
    Aaron Goldstein; Fiscal Year: 2009
    ..se/investors/annual_reports. 2005. 2. http://www.fda.gov/cdrh/MDA/DOCS/h020008.html. OP-1 Putty - H020008. 2004. 3. http://www.fda.gov/cdrh/mda/docs/p000058.html. InFUSE" Bone Graft/LT-CAGE" Lumbar Tapered Fusion Device - P000058. 2002. ..
  70. Role(s) of VEGF in Resolution of Inflammation
    Manuela M Martins Green; Fiscal Year: 2010
    ....
  71. Therapeutic Angiogenesis for Erectile Dysfunction
    BRIAN ANNEX; Fiscal Year: 2009
    ..In this renewal, we propose to identify the mechanism for hypercholesterolemia induced vascular injury as well as how to employ information gained in the studies to advance potential treatments for ED...
  72. Reconstitution of thrombopoiesis by angiogenic factors
    Shahin Rafii; Fiscal Year: 2009
    ....
  73. BETA 1 INTEGRIN ANTAGONISM & RETINAL NEOVASCULARIZATION
    DONALD SENGER; Fiscal Year: 2001
    ..Moreover, it is anticipated that findings here will suggest new strategies for therapeutic intervention. ..
  74. REGULATION OF MACROPHAGE DEPENDENT ANGIOGENIC ACTIVITY
    SAMUEL LEIBOVICH; Fiscal Year: 2002
    ..abstract_text> ..
  75. Role of VEGF in Glomerular Endothelial Health & Diseases
    S Karumanchi; Fiscal Year: 2007
    ..abstract_text> ..
  76. Commercialization of iSONEP, a Humanized Monoclonal Antibody Against the Bioactiv
    ROGER ALLEN SABBADINI; Fiscal Year: 2010
    ....
  77. A Novel Model to Study Retinopathy of Prematurity
    David Moscatelli; Fiscal Year: 2003
    ..Our model will provide a useful tool to directly examine the roles of various factors in retinal vascular diseases in a setting that maintains normal tissue architecture. ..